28 Recruiting Acute Myeloid Leukemia Clinical Trials in Texas

Explore active acute myeloid leukemia research studies enrolling across Texas. Verify eligibility and contact site coordinators.

📍 Find Near Me by Distance

Browse by City

Houston

Recruiting Acute Myeloid Leukemia Studies in Texas

🔵 Active, Not Recruiting Early Phase1 🩺 Clinical Procedure Protocol

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

📍 MD Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 🧠 Behavioral & Psychological Program

Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

📍 Texas Children's Hospital — Houston, Texas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

📍 UT MD Anderson — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

📍 Texas Children's Cancer and Hematology Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

📍 MD Anderson — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Phase I Study of HC-7366 for Acute Myeloid Leukemia

📍 MD Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

📍 MD Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

📍 MD Anderson — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

📍 MD Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

📍 M D Anderson Cancer Center — Houston, Texas

View Study & Checklist ➔